Delivery Order SPE2DR25D2006-SPE2DR26F56EU
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,783.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on November 18, 2025, with completion expected by November 19, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively to the prime contractor at its corporate office location in Conshohocken, Pennsylvania. The order represents a single transaction under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,548.41 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on October 21, 2025, with an ultimate completion date of October 22, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,840.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed price, competitively awarded delivery order was issued on October 20, 2025, with an ultimate completion date of October 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $10,274.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract, with an ultimate completion date of November 5, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no...
- The Defense Logistics Agency (DLA) awarded a $9,986.53 delivery order contract to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price contract requires performance at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on July 26, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside order placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999. The order will be fulfilled from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $34,000 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on October 20, 2025. This firm fixed-price delivery order, which is not set-aside, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 21, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a $48,029.65 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on April 30, 2025, with completion scheduled for May 1, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,094.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes. The contract is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025, and was competitively awarded without set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location, supplying this...
- The Defense Logistics Agency awarded a $7,617.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on November 10, 2025, with an ultimate completion date of November 12, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at...
- SPE2DR25D2006Indefinite Delivery Contract
- SPE2DR25D2006-SPE2DR26F56EUDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $79,034.62 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on November 20, 2025, with an ultimate completion date of November 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and represents a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at $999.99 million through December 2026. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government entities. As the prime contractor on this delivery order, the company supplies brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. Dupixent is a biologic medication used to treat conditions such as atopic dermatitis, asthma, and eosinophilic esophagitis, underscoring the company's role in delivering specialized pharmaceutical products essential to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $79.0k | 11/20/25 |